Administration of flurbiprofen axetil and dezocine for the postoperative analgesia in patients with non‑small cell lung cancer: A randomized, controlled study

Wei,Xiaona; Wang,Zhigang; Chen,Yongxue; Wang,Xiaowei; Ma,Long; Hou,Junde; Zhao,Lu

doi:10.3892/ol.2024.14426

Administration of flurbiprofen axetil and dezocine for the postoperative analgesia in patients with non‑small cell lung cancer: A randomized, controlled study

Authors:
- Xiaona Wei
- Zhigang Wang
- Yongxue Chen
- Xiaowei Wang
- Long Ma
- Junde Hou
- Lu Zhao
View Affiliations

Affiliations: Department of Anesthesiology, Handan Central Hospital, Handan, Hebei 056008, P.R. China
Published online on: May 1, 2024 https://doi.org/10.3892/ol.2024.14426
Article Number: 294
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Flurbiprofen axetil or dezocine monotherapy has been applied for analgesia of postoperative non‑small cell lung cancer (NSCLC); however, their combination is rarely investigated. Consequently, the present study aimed to explore the effect of flurbiprofen axetil plus dezocine on postoperative pain, surgical outcomes and its safety profile in patients with NSCLC. A total of 150 patients with resectable NSCLC were enrolled and randomized into three groups: i) The flurbiprofen axetil plus dezocine group (n=50), ii) the flurbiprofen axetil group (n=51) and iii) the dezocine group (n=49). A total of 50 mg flurbiprofen axetil, 5 mg of dezocine or their combination were administered intravenously 3 h prior to surgery and subsequently every 12 h until day 3 (D3) following surgery. The postoperative pain was lower in the flurbiprofen axetil plus dezocine group compared with that of the flurbiprofen axetil group at 6 h (P=0.008), 12 h (P=0.003), day 1 (D1) (P=0.013), day 2 (D2) (P=0.036) and D3 (P=0.010); in addition, it was lower in the flurbiprofen axetil plus dezocine group compared with that of the dezocine group at 6 h (P=0.010), 12 h (P=0.012) and D1 (P=0.020). Patient‑controlled analgesia consumption was also lower in the flurbiprofen axetil plus dezocine group compared with that of the flurbiprofen axetil (P=0.010) and dezocine (P=0.002) groups. Furthermore, the length of hospital stay was lower in the flurbiprofen axetil plus dezocine group compared with that of the flurbiprofen axetil (P=0.008) and dezocine (P=0.048) groups, while other surgical outcomes and adverse events were similar among these three groups. Moreover, the expression of tumor necrosis factor‑α was lower in the flurbiprofen axetil plus dezocine group compared with that of the dezocine group at 12 h (P<0.001), D1 (P<0.001) and D3 (P=0.033). The data indicated that flurbiprofen axetil and dezocine combination was superior to monotherapy for postoperative analgesia in patients with resectable NSCLC.

View Figures

View References

1	Oliver AL: Lung Cancer: Epidemiology and screening. Surg Clin North Am. 102:335–344. 2022. View Article : Google Scholar : PubMed/NCBI
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
3	Chen P, Liu Y, Wen Y and Zhou C: Non-small cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022. View Article : Google Scholar : PubMed/NCBI
4	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, et al: Non-Small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:497–530. 2022. View Article : Google Scholar : PubMed/NCBI
5	Marshall K and McLaughlin K: Pain management in thoracic surgery. Thorac Surg Clin. 30:339–346. 2020. View Article : Google Scholar : PubMed/NCBI
6	Geng C, Tong C, Li H, Shi S, Yu J and Huang L: Effects of thoracic paravertebral block on postoperative anxiety and depression for patients undergoing thoracoscopic lung cancer radical surgery. Comput Math Methods Med. 2022:76290122022. View Article : Google Scholar : PubMed/NCBI
7	Fregoso G, Wang A, Tseng K and Wang J: Transition from acute to chronic pain: Evaluating risk for chronic postsurgical pain. Pain Physician. 22:479–488. 2019.PubMed/NCBI
8	Gupta R, Van de Ven T and Pyati S: Post-Thoracotomy Pain: Current strategies for prevention and treatment. Drugs. 80:1677–1684. 2020. View Article : Google Scholar : PubMed/NCBI
9	Bindu S, Mazumder S and Bandyopadhyay U: Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 180:1141472020. View Article : Google Scholar : PubMed/NCBI
10	Seifert O and Baerwald C: Interaction of pain and chronic inflammation. Z Rheumatol. 80:205–213. 2021. View Article : Google Scholar : PubMed/NCBI
11	Huang L, Zheng X, Zhang Y, Lin Y, Lin L, Gao Y and Lin X: Flurbiprofen axetil alleviates the effect of formalin-induced inflammatory pain on the cognitive function of rats with mild cognitive impairment through the AMPKα/NF-κB signaling pathway. Ann Transl Med. 10:12102022. View Article : Google Scholar : PubMed/NCBI
12	Li X, Yu L, Yang J and Tan H: Multimodal analgesia with ropivacaine wound infiltration and intravenous flurbiprofen axetil provides enhanced analgesic effects after radical thyroidectomy: A randomized controlled trial. BMC Anesthesiol. 19:1672019. View Article : Google Scholar : PubMed/NCBI
13	Zong S, Du J, Chen Y and Tao H: Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function. J BUON. 26:1432–1439. 2021.PubMed/NCBI
14	An B and Dong W: Effects of multimodal analgesia of flurbiprofen axetil, nalbuphine and patient controlled intravenous analgesia on inflammatory factor levels and stress response in patients after laparoscopic radical gynecological malignancy surgery. Pak J Pharm Sci. 35((2(Special))): 641–647. 2022.PubMed/NCBI
15	Zhu R, Du T and Gao H: Effects of dezocine and ropivacaine infiltration anesthesia on cellular immune function indicators, anesthesia recovery time and pain factors in patients with open liver resection. Cell Mol Biol (Noisy-le-grand). 66:149–154. 2020. View Article : Google Scholar : PubMed/NCBI
16	Hu X, Luo B, Wu Q, Chen Q, Lu P, Huang J, Liang X, Ling C and Li Y: Effects of dezocine and sufentanil on Th1/th2 balance in breast cancer patients undergoing surgery. Drug Des Devel Ther. 15:4925–4938. 2021. View Article : Google Scholar : PubMed/NCBI
17	Ye RR, Jiang S, Xu X, Lu Y, Wang YJ and Liu JG: Dezocine as a potent analgesic: Overview of its pharmacological characterization. Acta Pharmacol Sin. 43:1646–1657. 2022. View Article : Google Scholar : PubMed/NCBI
18	Els C, Jackson TD, Kunyk D, Lappi VG, Sonnenberg B, Hagtvedt R, Sharma S, Kolahdooz F and Straube S: Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: An overview of Cochrane Reviews. Cochrane Database Syst Rev. 10:CD0125092017.PubMed/NCBI
19	Yamanaka T and Sadikot RT: Opioid effect on lungs. Respirology. 18:255–262. 2013. View Article : Google Scholar : PubMed/NCBI
20	Coussens NP, Sittampalam GS, Jonson SG, Hall MD, Gorby HE, Tamiz AP, McManus OB, Felder CC and Rasmussen K: The Opioid Crisis and the Future of Addiction and Pain Therapeutics. J Pharmacol Exp Ther. 371:396–408. 2019. View Article : Google Scholar : PubMed/NCBI
21	Hsu JR, Mir H, Wally MK and Seymour RB; Orthopaedic Trauma Association Musculoskeletal Pain Task Force, : Clinical practice guidelines for pain management in acute musculoskeletal injury. J Orthop Trauma. 33:e158–e182. 2019. View Article : Google Scholar : PubMed/NCBI
22	Chen YK, Boden KA and Schreiber KL: The role of regional anaesthesia and multimodal analgesia in the prevention of chronic postoperative pain: A narrative review. Anaesthesia. 76 Suppl 1:S8–S17. 2021. View Article : Google Scholar
23	Ye H, Lian X, Chen R, Zhu Y, Chen H, Huang J, Xie L, Ma W, Yang H and Guo W: Intraoperative administration of intravenous flurbiprofen axetil with nalbuphine reduces postoperative pain after orbital decompression: A single-center, prospective randomized controlled trial. J Pain Res. 12:659–665. 2019. View Article : Google Scholar : PubMed/NCBI
24	Wu LX, Dong YP, Zhu QM, Zhang B, Ai BL, Yan T, Zhang GH and Sun L: Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain. BMC Cancer. 21:11282021. View Article : Google Scholar : PubMed/NCBI
25	Cohen SP, Vase L and Hooten WM: Chronic pain: An update on burden, best practices, and new advances. Lancet. 397:2082–2097. 2021. View Article : Google Scholar : PubMed/NCBI
26	De Giorgio R, Zucco FM, Chiarioni G, Mercadante S, Corazziari ES, Caraceni A, Odetti P, Giusti R, Marinangeli F and Pinto C: Management of opioid-induced constipation and bowel dysfunction: Expert opinion of an Italian multidisciplinary panel. Adv Ther. 38:3589–3621. 2021. View Article : Google Scholar : PubMed/NCBI